Home
INCY
INCY News

Latest Incyte Corp. (INCY) News on June 1, 2025

Morningstar Research

2 days ago

Analyst Report: Incyte Corporation

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?

Zacks

2 days ago

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?

Incyte to Present at Upcoming Investor Conference

Business Wire

5 days ago

Incyte to Present at Upcoming Investor Conference

MT Newswires

5 days ago

Truist Securities Adjusts Price Target on Incyte to $73 From $72, Maintains Hold Rating

3 Reasons INCY is Risky and 1 Stock to Buy Instead

StockStory

10 days ago

3 Reasons INCY is Risky and 1 Stock to Buy Instead

3 Mid-Cap Stocks with Questionable Fundamentals

StockStory

12 days ago

3 Mid-Cap Stocks with Questionable Fundamentals

FDA approves Incyte’s retifanlimab combo for SCAC treatment

Pharmaceutical Technology

13 days ago

FDA approves Incyte’s retifanlimab combo for SCAC treatment

Incyte Gets FDA Approval for Zynyz in New Cancer Indication

Zacks

15 days ago

Incyte Gets FDA Approval for Zynyz in New Cancer Indication

MT Newswires

16 days ago

Leerink Partners Adjusts Incyte Price Target to $96 From $95

MT Newswires

16 days ago

Incyte Says FDA Approves Zynyz for Anal Cancer Treatment

MT Newswires

16 days ago

Argus Lowers Price Target on Incyte to $75 From $80

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Business Wire

16 days ago

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Argus Research

16 days ago

Analyst Report: Incyte Corp.

Argus Research

16 days ago

Market Update: CSCO, FCX, INCY, XRX, SMCI

MT Newswires

17 days ago

Incyte to Pay Novartis $280 Million to Resolve Jakafi Royalties Dispute

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Insider Monkey

18 days ago

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance

StockStory

19 days ago

INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

24 days ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

What To Expect From Natera’s (NTRA) Q1 Earnings

StockStory

25 days ago

What To Expect From Natera’s (NTRA) Q1 Earnings

Thomson Reuters StreetEvents

25 days ago

Q1 2025 Syndax Pharmaceuticals Inc Earnings Call

MT Newswires

a month ago

Mizuho Adjusts Price Target on Incyte to $70 From $77, Maintains Neutral Rating

High Growth Tech Stocks in US with Strong Potential for Investors

Simply Wall St.

a month ago

High Growth Tech Stocks in US with Strong Potential for Investors

Incyte to Present at Upcoming Investor Conference

Business Wire

a month ago

Incyte to Present at Upcoming Investor Conference

MT Newswires

a month ago

Leerink Partners Raises Price Target on Incyte to $95 From $92

MT Newswires

a month ago

Stifel Lowers Price Target on Incyte to $75 From $77

MT Newswires

a month ago

TD Cowen Lowers Price Target on Incyte to $86 From $88

MT Newswires

a month ago

Morgan Stanley Adjusts Incyte's Price Target to $68 From $65

MT Newswires

a month ago

RBC Raises Price Target on Incyte to $67 From $64, Keeps Sector Perform Rating

Incyte First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

a month ago

Incyte First Quarter 2025 Earnings: Beats Expectations

Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

GuruFocus.com

a month ago

Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

Morningstar Research

a month ago

Analyst Report: Incyte Corporation

MT Newswires

a month ago

Wells Fargo Hikes Price Target on Incyte to $59 From $58

MT Newswires

a month ago

Jefferies Adjusts Incyte Price Target to $76 From $75

INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales

Zacks

a month ago

INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales

Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings

Zacks

a month ago

Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings

3 Value Stocks Facing Headwinds

StockStory

a month ago

3 Value Stocks Facing Headwinds

Incyte (INCY) Q1 Earnings and Revenues Top Estimates

Zacks

a month ago

Incyte (INCY) Q1 Earnings and Revenues Top Estimates

MT Newswires

a month ago

Incyte Q1 Adjusted Earnings, Revenue Rise

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

StockStory

a month ago

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

Associated Press Finance

a month ago

Incyte: Q1 Earnings Snapshot

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Business Wire

a month ago

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (INCY) Q1 Earnings Report Preview: What To Look For

StockStory

a month ago

Incyte (INCY) Q1 Earnings Report Preview: What To Look For

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Zacks

a month ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

Business Wire

a month ago

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a month ago

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

3 Cash-Heavy Stocks Skating on Thin Ice

StockStory

a month ago

3 Cash-Heavy Stocks Skating on Thin Ice

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire

a month ago

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know

Zacks

a month ago

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

a month ago

Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth

MT Newswires

a month ago

JPMorgan Adjusts Incyte Price Target to $68 From $70, Maintains Neutral Rating

MT Newswires

a month ago

BofA Adjusts Price Target on Incyte to $87 From $86, Keeps Buy Rating

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

StockStory

2 months ago

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

MT Newswires

2 months ago

Incyte Faces Limited Exposure From Tariffs on Dual Sourcing, UBS Says

Incyte to Report First Quarter Financial Results

Business Wire

2 months ago

Incyte to Report First Quarter Financial Results

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

StockStory

2 months ago

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Zacks

2 months ago

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks In The US Market

MT Newswires

2 months ago

RBC Lowers Price Target on Incyte to $64 From $68, Keeps Sector Perform Rating

3 Reasons INCY is Risky and 1 Stock to Buy Instead

StockStory

2 months ago

3 Reasons INCY is Risky and 1 Stock to Buy Instead

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

GlobeNewswire

2 months ago

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

MT Newswires

2 months ago

Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating

Why Incyte Stock Was Tanking This Week

Motley Fool

2 months ago

Why Incyte Stock Was Tanking This Week

1 Healthcare Stock on Our Watchlist and 2 to Brush Off

StockStory

2 months ago

1 Healthcare Stock on Our Watchlist and 2 to Brush Off

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Zacks

2 months ago

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Incyte Had a Bad Week. Investors Are Used to It.

Barrons.com

2 months ago

Incyte Had a Bad Week. Investors Are Used to It.

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

Zacks

2 months ago

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

StockStory

2 months ago

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Incyte price target lowered to $72 from $74 at Truist

TipRanks

2 months ago

Incyte price target lowered to $72 from $74 at Truist

Morningstar Research

2 months ago

Analyst Report: Incyte Corporation

INCY Stock Down on Disappointing Skin Disease Study Data

Zacks

2 months ago

INCY Stock Down on Disappointing Skin Disease Study Data

Stoke CEO exits; Medicare drug price talks advance

BioPharma Dive

2 months ago

Stoke CEO exits; Medicare drug price talks advance

MT Newswires

2 months ago

Guggenheim Downgrades Incyte to Neutral From Buy

MT Newswires

2 months ago

Jefferies Adjusts Price Target on Incyte to $75 From $81, Keeps Buy Rating

MT Newswires

2 months ago

Deutsche Bank Adjusts Price Target on Incyte to $60 From $70, Keeps Hold Rating

MT Newswires

2 months ago

Truist Securities Adjusts Price Target on Incyte to $72 From $74, Keeps Hold Rating

MT Newswires

2 months ago

William Blair Downgrades Incyte to Market Perform From Outperform

Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires

Insider Monkey

2 months ago

Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires

Incyte stock dives after drug trial disappoints investors

Yahoo Finance Video

2 months ago

Incyte stock dives after drug trial disappoints investors

S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision

Investopedia

2 months ago

S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision

Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Investor's Business Daily

2 months ago

Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Nvidia, Netflix, Berkshire Hathaway, Baidu, Lockheed Martin, Incyte, NCL, Affirm: Stocks to watch today

Quartz

2 months ago

Nvidia, Netflix, Berkshire Hathaway, Baidu, Lockheed Martin, Incyte, NCL, Affirm: Stocks to watch today

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

Business Wire

2 months ago

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?

Zacks

3 months ago

Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss

Benzinga

3 months ago

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps

Benzinga

3 months ago

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps

INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies

Zacks

3 months ago

INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies

LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study

Zacks

3 months ago

LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study

MT Newswires

3 months ago

Eli Lilly, Incyte Report Significant Hair Regrowth in Adolescents Treated With Baricitinib

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

PR Newswire

3 months ago

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

Business Wire

3 months ago

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

3 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

3 months ago

Incyte Insider Sold Shares Worth $1,042,136, According to a Recent SEC Filing

Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?

Insider Monkey

3 months ago

Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

Business Wire

3 months ago

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

High Growth Tech Stocks to Watch in US Market February 2025

Simply Wall St.

3 months ago

High Growth Tech Stocks to Watch in US Market February 2025

Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery

Insider Monkey

3 months ago

Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery

Argus Research

3 months ago

Market Digest: ALB, BAX, CHH, INCY, KBH, MCK, SO, HUBS, TRGP

Argus Research

3 months ago

Analyst Report: Incyte Corp.

Incyte and Genesis collaborate on small-molecule medicines

Pharmaceutical Technology

3 months ago

Incyte and Genesis collaborate on small-molecule medicines

Share on Social Networks: